# Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status

> **NCT04169178** · PHASE1 · UNKNOWN · sponsor: **Henlix, Inc** · enrollment: 98 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** HLX55

## Key facts

- **NCT ID:** NCT04169178
- **Lead sponsor:** Henlix, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-03
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04169178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04169178, "Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04169178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*